Queen Máxima visits the RadboudUMC and learns about holmium technology
28 January 2021 – NIJMEGEN – Today Her Majesty the Queen Máxima paid a virtual working visit to the RadboudUMC. During the visit, she focused
Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to facilitate patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in four simple steps:
28 January 2021 – NIJMEGEN – Today Her Majesty the Queen Máxima paid a virtual working visit to the RadboudUMC. During the visit, she focused
09/12/2020 – LEUVEN, BELGIUM Quirem Medical, a Terumo company, is awarded top 3 innovative medical device in the 2019 Belgian Galenus prize with the innovative
20 OCTOBER 2020, DEVENTER – Today a first clinical QuiremSpheres® patient procedure took place with a patient dose prepared using a novel hotlab manufacturing process
TOKYO and DEVENTER, Netherlands, July 15, 2020 — Terumo Corporation (TSE: 4543) today announced it has completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in
DEVENTER, Jun. 8 2020 – Quirem Medical announced today it received CE-mark approval for the latest version of Q-Suite®, dosimetry software for holmium-166 SIRT. Q-Suite®
Terumo Europe N.V. and Quirem Medical B.V are proud to share the latest key publication regarding holmium-166 (QuiremSpheres®) Selective Internal Radiation Therapy (SIRT). On 27
Radiology of the Future revolves around smart and fast image processing. Achieving this requires research and entrepreneurship. This is the reason that Thirona, Quirem, and
29 January 2020 – LEIPZIG On Wednesday 29th of January 2020 a QuiremSpheres® live case was performed to treat a patient suffering from intrahepatic cholangiocellular
Quirem Medical is pleased to share that yet another Holmium-166 (QuiremSpheres®) related scientific article has been published, after recently having reported on the publication of
Radboud university medical center and Quirem Medical today signed an agreement for joint research. The agreement includes several existing and future projects based on small
Telephone: +31 85 0404170
E-mail: info.quirem@terumo-europe.com
Necessary cookies help make a website more usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
Statistical cookies help us understand how visitors use the website by collecting and reporting data anonymously. These cookies therefore do not collect any personal data from visitors.
Cookies are small text files that can be used by websites to make user experiences more efficient. By law, we may store cookies on your device if they are strictly necessary for the use of the website. These are the functional cookies. We need your consent for all other types of cookies. These cookies are named as: preferences and statistics and you do not have to accept them. This website uses different types of cookies. Some cookies are placed by third party services that are displayed on our pages.